Frontier Medicines, FMC-376, KRAS G12C, NSCLC, Non-Small Cell Lung Cancer, KRAS Inhibitor, ON/OFF Inhibitor, Precision Medicine, Targeted Therapy, Phase 1 Trial, Phase 2 Trial

BOSTON and SOUTH SAN FRANCISCO, Calif. — October 25, 2026 Frontier Medicines Corporation announced preliminary Phase 1a results for...